29 May 2025 ·

GPZL Welcomes Two New Representatives of National Leprosy Programme to the Members’ Assembly (Global Board)

The Global Partnership for Zero Leprosy (GPZL) is proud to announce the election of two new Representatives of National Leprosy Programmes to its Members’ Assembly (Global Board): Dr. Munirah Abdullahi Onimisi from Nigeria and Dr. Rabindra Baskota from Nepal. Their election reflects the GPZL’s commitment … Read More >

8 May 2025 ·

Political Commitment Catalyses Leprosy Elimination Efforts

Kathmandu | 8–9 May 2025 Nepal is demonstrating bold political leadership in the fight against leprosy. Our Executive Director, Dr. Ritu Ghosh is attending the Nepal Leprosy Conference, a pivotal high-level event aimed at accelerating national efforts toward a leprosy-free Nepal. She is participating as … Read More >

1 May 2025 ·

GPZL Executive Director to Join High-Level Discussion on Leprosy in India

We are pleased to announce that Ritu Ghosh, Executive Director of the Global Partnership for Zero Leprosy (GPZL), will be a panellist at the upcoming event “Leprosy in India: Down but Not Out. What Are We Doing About It?” The event, , will take place … Read More >

6 April 2025 ·

Announcement: Jephiter Tsamwi joins GPZL team

We are excited to welcome Jephiter Tsamwi to the GPZL team as Manager – Communications and Digital Engagement. His experience and commitment will play a key role in strengthening our communication efforts and driving meaningful engagement. We look forward to the contributions he will bring to our shared mission.

GPZL 2020 Impact Report

Our 2020 impact report highlights our work in COVID-19 response, leprosy research, and country partnerships.

Download

COVID-19 & Leprosy Resources

Visit the Zero Leprosy COVID-19 hub for the latest advice, resources, and news related to leprosy during the COVID-19 pandemic.

Visit site

WHO Technical Guidance: Leprosy/Hansen’s disease contact tracing and post-exposure prophylaxis

“In order to bring down the case detection among leprosy contacts from Point A to Point B, programmes can choose to treat 100 contacts with leprosy and nobody with chemoprophylaxis or provide chemoprophylaxis to all contacts and treat only 43 leprosy patients”. The latter choice is the most obvious for many programmes. This document provides guidance on how to implement contact screening and chemoprophylaxis with single-dose rifampicin. The contents are logically ordered: counselling and obtaining consent, identification and listing of index case, listing of contacts, tracing of contacts, screening of contacts, administration of prophylactic drugs. Managerial aspects to undertake contact screening and chemoprophylaxis are also elaborated, including planning, training, supervision and drug management.

Visit site